NRX Pharmaceuticals, Inc.
NRXP Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$2.55
KIRA · Stoqly’s AI analyst, in plain words
- NRX Pharmaceuticals, Inc. had $1.2M of revenue in fiscal 2025. Over five years, revenue changed +54.6% a year on average.
- Its operating margin was −1,324.4%: of every 100 in sales, about −1,324 is left after running the business.
- NRX Pharmaceuticals, Inc. lost $28.6M in fiscal 2025.
Market cap
—
P/E
—
Revenue
$1.2M
Net income
−$28.6M
Free cash flow
—
Operating margin
−1,324.4%
NRX Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−2,336.5%
No. It lost money last year.
What NRX Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 23, 2026
- Legal name
- NRX Pharmaceuticals, Inc.
- CIK
- 0001719406
NRX Pharmaceuticals, Inc. · NRXP
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | $0.0M | $0.0M | $1.2M |
| Gross margin | — | — | — | — | 58.8% |
| Operating margin | — | — | — | — | −1,324.4% |
| Net income | −$93.1M | −$39.8M | −$30.2M | −$25.1M | −$28.6M |
| Net margin | — | — | — | — | −2,336.5% |
| Diluted EPS | −$1.98 | −$0.60 | — | — | — |
| Cash | |||||
| Cash from operations | −$37.7M | −$39.8M | −$21.7M | −$10.6M | −$14.1M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Free cash flow | −$37.7M | −$39.8M | −$21.7M | −$10.6M | — |
| Share count change | 36.9% | 40.2% | — | — | — |
| Debt and strength | |||||
| Cash and short-term investments | $27.6M | $20.1M | $4.6M | $1.4M | $7.8M |
| Debt incl. finance leases | — | $10.5M | $9.2M | — | — |
| Shareholders' equity | $20.8M | $7.4M | −$11.7M | −$23.2M | −$15.9M |
| Current ratio | 2.7x | 1.7x | 0.4x | 0.2x | 0.3x |
| Interest coverage | −6,433.1x | — | −232.0x | −80.4x | −24.2x |
| Returns and quality | |||||
| Return on equity | — | −281.8% | — | — | — |
| Return on tangible equity | −1,676.8% | −536.6% | — | — | — |
| Altman Z'' | −36.0 | −36.7 | −149.9 | −316.8 | −96.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
NRX Pharmaceuticals, Inc. · NRXP
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.55 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001719406). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.